SEC Form 4 · accession 0001061983-26-000086
CYTOKINETICS INC · CYTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Callos
Officer — EVP, Chief Commercial Officer
Period of report
Jul 30, 2026
Accepted (ET)
Jul 30, 2026 · 4:26 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001061983
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 30, 2026 | M | 14,000 | $23.26 | A | 72,555 | D | |
| Common Stock | Jul 30, 2026 | S | 14,000 | $79.88 | D | 58,555 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $23.26 | Jul 30, 2026 | M | 14,000 | D | Mar 31, 2022 | Mar 31, 2031 | Common Stock | 14,000 | 10,000 | D |
Explanation of responses
- F1Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.